rAd-IFN α/Syn3 Promising in BCG-Refractory and Relapsed High-Grade Nonmuscle-Invasive Bladder Cancer

Intravesical rAd-IFN α/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

Source: CancerNetwork - February 18, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: ASCO Genitourinary Cancers Symposium Bladder Cancer News Source Type: news